Literature DB >> 7554500

Epidemiology of the leishmaniases.

A J Magill1.   

Abstract

The leishmaniases are a group of zoonotic infections caused by protozoan parasites of the genus Leishmania. These infections produce a variety of different clinical diseases depending on the virulence or tropism of the parasite and differential host immune responses. Newly recognized clinical presentations, such as viscerotropic leishmaniasis in American military veterans of Operation Desert Storm, continue to challenge clinicians. Epidemics of classic visceral leishmaniasis leading to thousands of deaths are ongoing in Brazil, India, and the Sudan. Epidemics of localized cutaneous leishmaniasis are ongoing in many areas of South America, North Africa, and Central Asia. A marked increase in cases is often associated with an influx of nonimmune populations into newly cleared agricultural populations into newly cleared agricultural areas or population expansion into previously unsettled areas surrounding cities. The emergence of leishmaniasis as an important opportunistic infection in AIDS patients portends an ominous future as the HIV pandemic sweeps into the hyperendemic areas of South America, Africa, and the Indian subcontinent. Parenteral transmission via needle sharing in HIV coinfected individuals in Spain is an epidemiologically significant new mode of transmission. Finally, recent work has elucidated an enzootic transmission cycle involving L. mexicana in Texas.

Entities:  

Mesh:

Year:  1995        PMID: 7554500

Source DB:  PubMed          Journal:  Dermatol Clin        ISSN: 0733-8635            Impact factor:   3.478


  12 in total

1.  Multilevel modelling of the incidence of visceral leishmaniasis in Teresina, Brazil.

Authors:  G L Werneck; C H N Costa; A M Walker; J R David; M Wand; J H Maguire
Journal:  Epidemiol Infect       Date:  2006-07-07       Impact factor: 2.451

Review 2.  Recent developments and future prospects in the treatment of visceral leishmaniasis.

Authors:  Shyam Sundar; Anup Singh
Journal:  Ther Adv Infect Dis       Date:  2016-04-22

Review 3.  An update on pharmacotherapy for leishmaniasis.

Authors:  Shyam Sundar; Jaya Chakravarty
Journal:  Expert Opin Pharmacother       Date:  2014-10-25       Impact factor: 3.889

4.  Investigational drugs for visceral leishmaniasis.

Authors:  Shyam Sundar; Jaya Chakravarty
Journal:  Expert Opin Investig Drugs       Date:  2014-11-20       Impact factor: 6.206

5.  Gender is a major determinant of the clinical evolution and immune response in hamsters infected with Leishmania spp.

Authors:  Bruno L Travi; Yaneth Osorio; Peter C Melby; Bysani Chandrasekar; Lourdes Arteaga; Nancy G Saravia
Journal:  Infect Immun       Date:  2002-05       Impact factor: 3.441

6.  Vaccination with plasmid DNA encoding TSA/LmSTI1 leishmanial fusion proteins confers protection against Leishmania major infection in susceptible BALB/c mice.

Authors:  A Campos-Neto; J R Webb; K Greeson; R N Coler; Y A W Skeiky; S G Reed
Journal:  Infect Immun       Date:  2002-06       Impact factor: 3.441

7.  The biology and control of leishmaniasis vectors.

Authors:  David M Claborn
Journal:  J Glob Infect Dis       Date:  2010-05

8.  Drug resistance in leishmaniasis.

Authors:  Jaya Chakravarty; Shyam Sundar
Journal:  J Glob Infect Dis       Date:  2010-05

9.  Intradermal infection model for pathogenesis and vaccine studies of murine visceral leishmaniasis.

Authors:  Saeed Ahmed; M Colmenares; L Soong; K Goldsmith-Pestana; L Munstermann; R Molina; Diane McMahon-Pratt
Journal:  Infect Immun       Date:  2003-01       Impact factor: 3.441

10.  Vaccines for canine leishmaniasis.

Authors:  Clarisa B Palatnik-de-Sousa
Journal:  Front Immunol       Date:  2012-04-17       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.